PMID- 33790648
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 13
DP  - 2021
TI  - Long Noncoding RNA GAS5 Accelerates Cholangiocarcinoma Progression by Regulating 
      hsa-miR-1297.
PG  - 2745-2753
LID - 10.2147/CMAR.S297868 [doi]
AB  - BACKGROUND: Long noncoding RNAs (lncRNAs) have been reported as important 
      molecules in cholangiocarcinoma (CCA) occurrence and development. A previous 
      study showed that lncRNA GAS5 (GAS5) was an oncogene in some tumors. But the role 
      of GAS5 in CCA progression reminds unclear. This research was designed to study 
      the expression and potential effects of GAS5 in the progression of CCA. METHODS: 
      The expression of GAS5 in CCA tissues was evaluated through mining of the TCGA 
      and GEPIA databases. qRT-PCR was applied to validate the results in our clinical 
      samples. chi (2) test was used to analyze the association between the expression 
      level of tissue GAS5 and different clinicopathological parameters of CCA 
      patients. The target gene of GAS5 was predicted by bioinformatic databases, and 
      further verified by luciferase reporter assays. Finally, the role of GAS5 in CCA 
      cells invasion and proliferation was detected by Transwell assay and CCK-8 assay. 
      RESULTS: Compared to the adjacent nontumor tissues and the normal human 
      intrahepatic biliary epithelial cell, the expression of GAS5 was markedly 
      increased in CCA tissues (p<0.001) and cell lines (p<0.01), respectively. CCA 
      patients with high GAS5 expression tended to present lymph node metastasis 
      (p<0.001) and had advanced clinical stage (p=0.006). The bioinformatics analysis 
      predicted that hsa-miR-1297 was the potential target gene of GAS5, which was 
      validated by luciferase reporter assays. In addition, the function study showed 
      that GAS5 acted as a "sponge" to downregulate hsa-miR-1297, thus modulating CCA 
      cell proliferation and invasion. CONCLUSION: GAS5 acts as an endogenous sponge of 
      hsa-miR-1297 to promote CCA cell proliferation and invasion, which might be a 
      potential biomarker and therapeutic target for CCA.
CI  - (c) 2021 Li et al.
FAU - Li, Qian
AU  - Li Q
AD  - Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, 
      Henan Cancer Hospital, Zhengzhou, 450008, Henan, People's Republic of China.
FAU - Fu, Lei
AU  - Fu L
AD  - Department of Oncology, People's Hospital of Zhengzhou University, Henan 
      Provincial People's Hospital, Zhengzhou, 450003, Henan, People's Republic of 
      China.
FAU - Han, Lili
AU  - Han L
AD  - Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, 
      Henan Cancer Hospital, Zhengzhou, 450008, Henan, People's Republic of China.
FAU - Li, Shuai
AU  - Li S
AD  - Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, 
      Henan Cancer Hospital, Zhengzhou, 450008, Henan, People's Republic of China.
FAU - Zhang, Yanling
AU  - Zhang Y
AD  - Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, 
      Henan Cancer Hospital, Zhengzhou, 450008, Henan, People's Republic of China.
FAU - Wang, Jufeng
AU  - Wang J
AD  - Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, 
      Henan Cancer Hospital, Zhengzhou, 450008, Henan, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210323
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC8001187
OTO - NOTNLM
OT  - GAS5
OT  - invasion
OT  - metastasis
OT  - miR-1297
OT  - proliferation
COIS- The authors declare that they have no competing interests in this work.
EDAT- 2021/04/02 06:00
MHDA- 2021/04/02 06:01
PMCR- 2021/03/23
CRDT- 2021/04/01 06:24
PHST- 2020/12/31 00:00 [received]
PHST- 2021/02/26 00:00 [accepted]
PHST- 2021/04/01 06:24 [entrez]
PHST- 2021/04/02 06:00 [pubmed]
PHST- 2021/04/02 06:01 [medline]
PHST- 2021/03/23 00:00 [pmc-release]
AID - 297868 [pii]
AID - 10.2147/CMAR.S297868 [doi]
PST - epublish
SO  - Cancer Manag Res. 2021 Mar 23;13:2745-2753. doi: 10.2147/CMAR.S297868. 
      eCollection 2021.